Stockscreener 앱 받기
2.90
2.68%
-0.08
시간 외 거래:
2.86
-0.04
-1.38%
Macrogenics Inc 주식(MGNX)의 최신 뉴스
Sentiment Review: Will MacroGenics Inc outperform the market in YEAR2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Why is MacroGenics stock sinking Tuesday? - MSN
Bull Run: Is MacroGenics Inc attractive for institutional investorsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Who's Buying or Selling Macrogenics Inc (HAM:M55) Stock Today? - GuruFocus
Macrogenics Inc (HAM:M55) DCF Valuation - GuruFocus
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
Stifel reiterates MacroGenics stock rating with $4 price target By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com Australia
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Asianet Newsable
MGNX: Focused execution and pipeline progress set up major clinical milestones for mid-2026 - TradingView
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Ma - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
MacroGenics : Corporate Overview March 2026 - marketscreener.com
MacroGenics (NASDAQ: MGNX) details 2025 results, cash runway and key 2026 data - Stock Titan
MacroGenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
MacroGenics Q1 2025 Earnings Preview - MSN
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX SEC FilingsMacrogenics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics at TD Cowen Conference: Strategic Imperatives in Focus - Investing.com
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
MacroGenics, Inc. Announces Jay Siegel Not Stands for Re-Election as Class I Director, Effective February 25, 2026 - marketscreener.com
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
FDA Partially Pauses Cancer Drug Trial After Patient Death - National Today
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com Australia
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
1.20%
0.06%
자본화:
|
볼륨(24시간):